臨床検査51巻7号

2007年07月発行

今月の主題 不整脈検査 不整脈の検査

心房細動の血栓塞栓予防における血液凝固系検査

著者： 藤木明¹

所属機関： ¹富山大学医学部第2内科

ページ範囲：P.726 - P.730

　心房細動の血栓塞栓のリスクのなかでは年齢が大きな要因となる．しかし同じ年齢でも個々に異なるリスクを，凝血分子マーカーで評価できれば意義は大きい．血栓塞栓症の治療薬は凝固抑制のワルファリンと，血小板抑制のアスピリンとに大別される．これまでの大規模試験からワルファリンの効果は確立された．しかし心房細動例のなかには動脈硬化による塞栓を発症する例もあり，そのような場合にはアスピリンが有効な可能性がある．個々に異なる塞栓症のリスク要因が凝血分子マーカーで判別できれば，塞栓症予防の特異的な治療選択も可能となろう．

参考文献

1) Wolf PA, Abbott RD, Kannel WB：Atrial fibrillation as an independent risk factor for stroke：the Framingham study. Stroke 22：983-988, 1991

2) Petersen P, Godtfredsen J, Boysen G, et al：Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation：the Copenhagen AFASAK Study. Lancet 333：175-179, 1989

3) Stroke Prevention in Atrial Fibrillation Investigators：Stroke prevention in atrial fibrillation study：final results. Circulation 84：527-539, 1991

4) Ezekowitz MD, Bridgers SL, James KE, et al：Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 327：1406-1412, 1992

5) Stroke Prevention in Atrial Fibrillation Investigators：Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation：stroke prevention in atrial fibrillation II study. Lancet 343：687-691, 1994

6) Stroke Prevention in Atrial Fibrillation Investigators：Adjusted dose warfarin versus low intensity, fixed dose, warfarin plus aspirin for high risk patients with atrial fibrillation：stroke prevention in atrial fibrillation III randomized clinical trials. Lancet 348：633-638, 1996

7) Atrial Fibrillation Investigators：Atrial fibrillation：risk factors for embolization and efficacy of antithrombotic therapy. Arch Intern Med 154：1449-1457, 1994

8) The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators：The effiect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 323：1505-1511, 1990

9) Connolly SJ, Laupacis A, Gent M, et al：Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 18：349-355, 1991

10) Lip GYH, Lip PL, Zarifis J, et al：Fibrin D-dimer and β-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Circulation 94：425-431, 1996

11) Kumagai K, Fukunami M, Ohmori M, et al：Incrased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol 16：377-380, 1990

12) Sohara H, Amitani S, Kurose M, et al：Atrial fibrillation activates platelets and coagulation in a time-dependent manner：A study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 29：106-112, 1997

13) Li-Saw-Hee FL, Blann AD, Gurney D, et al：Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J 22：1741-1747, 2001

14) Marin F, Roldan V, Climent VE, et al：Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. Heart 90：1162-1166, 2004

15) Kamath S, Blann AD, Caine GJ, et al：Platelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillation. Stroke 33：1237-1242, 2002

16) Conway DS, Buggins P, Hughes E, et al：Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 43：2075-2082, 2004

17) Enta K, Iwade K, Aosaki M, et al：Predictive value of coagulative molecular markers for Thromboembolism in patients with nonvalvular atrial fibrillation：prospective five-year. J Cardiology 44：223-232, 2004

18) Feinberg WM, Pearce LA, Hart RG, et al：Markers of thrombin and platelet activity in patients with atrial fibrillation：correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke 30：2547-2553, 1999